CL2023001224A1 - Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación - Google Patents

Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación

Info

Publication number
CL2023001224A1
CL2023001224A1 CL2023001224A CL2023001224A CL2023001224A1 CL 2023001224 A1 CL2023001224 A1 CL 2023001224A1 CL 2023001224 A CL2023001224 A CL 2023001224A CL 2023001224 A CL2023001224 A CL 2023001224A CL 2023001224 A1 CL2023001224 A1 CL 2023001224A1
Authority
CL
Chile
Prior art keywords
preparation
crystal form
receptor agonist
melanocortin receptor
agonist compound
Prior art date
Application number
CL2023001224A
Other languages
English (en)
Inventor
Ok HAM Jin
Yeon Lee Ho
Ah CHUN Seul
Dae Lee Sang
Won Park Jong
Yoon Kim Ji
Won Kim Sung
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2023001224A1 publication Critical patent/CL2023001224A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona a una forma cristalina II representada por la fórmula 1, un método para preparar la misma, y una composición farmacéutica que comprende la misma. La forma cristalina II representada por la fórmula 1 de la presente invención se puede caracterizar por patrones XRD, perfiles DSC y/o perfiles TGA.
CL2023001224A 2020-10-29 2023-04-27 Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación CL2023001224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200142397 2020-10-29

Publications (1)

Publication Number Publication Date
CL2023001224A1 true CL2023001224A1 (es) 2023-11-03

Family

ID=81384111

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001224A CL2023001224A1 (es) 2020-10-29 2023-04-27 Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación

Country Status (13)

Country Link
US (1) US20230399321A1 (es)
EP (1) EP4219473A4 (es)
JP (1) JP2023548163A (es)
KR (2) KR102672625B1 (es)
CN (1) CN116490497A (es)
AU (1) AU2021371829B2 (es)
CA (1) CA3195432A1 (es)
CL (1) CL2023001224A1 (es)
CO (1) CO2023006517A2 (es)
IL (1) IL302426A (es)
MX (1) MX2023004656A (es)
PE (1) PE20240124A1 (es)
WO (1) WO2022092910A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024501829A (ja) * 2020-12-22 2024-01-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉｉおよびその製造方法
CN116648249A (zh) * 2020-12-22 2023-08-25 株式会社Lg化学 黑皮质素受体激动剂化合物的结晶形式ii及其制备方法
CN116669743A (zh) * 2020-12-22 2023-08-29 株式会社Lg化学 黑皮质素受体激动剂化合物的结晶形式i及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1187614A4 (en) 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
US7157463B2 (en) 2001-01-23 2007-01-02 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
EP1685102A4 (en) * 2003-11-12 2008-08-20 Lg Life Sciences Ltd melanocortin
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
MX2019009463A (es) 2017-02-08 2019-12-16 Tilray Inc Metodo y aparatos para procesamiento de canabis a traves de energia radiante de baja presion.
DK3953327T3 (da) * 2019-11-07 2024-02-05 Lg Chemical Ltd Melanocortin-4-receptor-agonister

Also Published As

Publication number Publication date
MX2023004656A (es) 2023-05-18
AU2021371829A1 (en) 2023-06-01
KR102672625B1 (ko) 2024-06-07
CA3195432A1 (en) 2022-05-05
KR20220057471A (ko) 2022-05-09
WO2022092910A1 (ko) 2022-05-05
KR20240085231A (ko) 2024-06-14
US20230399321A1 (en) 2023-12-14
CN116490497A (zh) 2023-07-25
AU2021371829B2 (en) 2024-01-18
CO2023006517A2 (es) 2023-09-08
EP4219473A1 (en) 2023-08-02
PE20240124A1 (es) 2024-01-22
EP4219473A4 (en) 2024-03-13
JP2023548163A (ja) 2023-11-15
IL302426A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CL2023001224A1 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación
CL2023001222A1 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma
AR065272A1 (es) Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas
AR079152A1 (es) Inhibidores de glucosilceramida sintasa
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
AR079257A1 (es) Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
AR066158A1 (es) COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE.
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
AR083100A1 (es) Monohidrato de derivados de aza-adamantano
CL2023001221A1 (es) Agonista del receptor de melanocortina-4 amorfo
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
CL2020001346A1 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción.
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
AR085291A1 (es) Metodos para sintetizar derivados del precursor z de molibdopterina
BR112023022863A2 (pt) Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
MX2023013128A (es) Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.
MX2023013044A (es) Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
MX2023013129A (es) Forma cristalina iv de sales de acidos organicos del compuesto agonista del receptor de melanocortina y metodo de preparacion de este.
CL2022002821A1 (es) Compuestos de bencimidazol para el tratamiento de trastornos metabólicos